Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: C3 Glomerulonephritis Clear all
Withdrawn Phase 1 Interventional

TP10 Use in Patients With C3 Glomerulopathy (C3G)

NCT02302755
View directory record Official record
Conditions
Dense Deposit Disease
Interventions
TP10
Drug
Lead sponsor
University of Iowa
Other
Eligibility
4 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 21, 2026, 11:35 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721

NCT02682407
View directory record Official record
Conditions
IgAN, LN, MN, C3G
Interventions
OMS721 (narsoplimab)
Biological
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced Jul 21, 2026, 11:35 PM EDT
Active, not recruiting Phase 3 Interventional

An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05809531
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Los Angeles, California • Aurora, Colorado • Gainsville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted

NCT03832114
View directory record Official record
Conditions
Glomerulonephritis
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Jul 21, 2026, 11:35 PM EDT
Terminated Phase 1 Interventional

Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease

NCT01791686
View directory record Official record
Conditions
Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II, C3 Glomerulonephritis
Interventions
CDX-1135
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Results available

Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy

NCT01221181
View directory record Official record
Conditions
Dense Deposit Disease, Membranoproliferative Glomerulonephritis
Interventions
Eculizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

NCT05067127
View directory record Official record
Conditions
C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
Pegcetacoplan, Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

NCT03453619
View directory record Official record
Conditions
IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
17
States / cities
Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Daratumumab in Treatment of PGNMID and C3 GN

NCT03095118
View directory record Official record
Conditions
Membranoproliferative Glomerulonephritis
Interventions
Daratumumab
Drug
Lead sponsor
Fernando Fervenza
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Jul 21, 2026, 11:35 PM EDT
Terminated Phase 2 Interventional Results available

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

NCT03459443
View directory record Official record
Conditions
C3 Glomerulonephritis, C3 Glomerulopathy, Immune Complex Membranoproliferative Glomerulonephritis, IC-MPGN, Dense Deposit Disease
Interventions
Danicopan
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Birmingham, Alabama • Stanford, California • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

NCT04572854
View directory record Official record
Conditions
C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis
Interventions
Pegcetacoplan
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Controlled Trial Evaluating Avacopan in C3 Glomerulopathy

NCT03301467
View directory record Official record
Conditions
C3 Glomerulopathy (C3G)
Interventions
Avacopan, Avacopan Matching Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
10
States / cities
Palo Alto, California • Chicago, Illinois • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 21, 2026, 11:35 PM EDT
Recruiting Phase 3 Interventional

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

NCT03955445
View directory record Official record
Conditions
C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
Interventions
LNP023
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2036
U.S. locations
5
States / cities
Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 21, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)

NCT03369236
View directory record Official record
Conditions
C3 Glomerulopathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions
Danicopan, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
17 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Aurora, Colorado • Lawrenceville, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Jul 21, 2026, 11:35 PM EDT